CN111712257B - 携带双特异性T细胞衔接器（BiTE）的腺病毒 - Google Patents

携带双特异性T细胞衔接器（BiTE）的腺病毒 Download PDF

Info

Publication number
CN111712257B
CN111712257B CN201880055171.0A CN201880055171A CN111712257B CN 111712257 B CN111712257 B CN 111712257B CN 201880055171 A CN201880055171 A CN 201880055171A CN 111712257 B CN111712257 B CN 111712257B
Authority
CN
China
Prior art keywords
cells
ser
gly
bite
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880055171.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111712257A (zh
Inventor
B·查皮尔
A·C·N·布罗姆利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcamis Biology
Akamis Bio Ltd
Original Assignee
Arcamis Biology
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/071674 external-priority patent/WO2018041838A1/en
Application filed by Arcamis Biology, Psioxus Therapeutics Ltd filed Critical Arcamis Biology
Priority to CN202311294743.XA priority Critical patent/CN119432918A/zh
Publication of CN111712257A publication Critical patent/CN111712257A/zh
Application granted granted Critical
Publication of CN111712257B publication Critical patent/CN111712257B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201880055171.0A 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒 Active CN111712257B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311294743.XA CN119432918A (zh) 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1713765.4A GB201713765D0 (en) 2017-08-28 2017-08-28 Modified adenovirus
GB1713765.4 2017-08-28
PCT/EP2017/071674 WO2018041838A1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
EPPCT/EP2017/071674 2017-08-29
PCT/EP2017/071655 WO2018041827A1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
EPPCT/EP2017/071655 2017-08-29
PCT/EP2018/073160 WO2019043020A1 (en) 2017-08-28 2018-08-28 ADENOVIRUS EQUIPPED WITH A BISPECIFIC T CELL ACTIVATOR (BITE)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311294743.XA Division CN119432918A (zh) 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒

Publications (2)

Publication Number Publication Date
CN111712257A CN111712257A (zh) 2020-09-25
CN111712257B true CN111712257B (zh) 2023-10-27

Family

ID=60037191

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880055171.0A Active CN111712257B (zh) 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒
CN202311294743.XA Pending CN119432918A (zh) 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311294743.XA Pending CN119432918A (zh) 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒

Country Status (20)

Country Link
US (2) US11840702B2 (enExample)
EP (2) EP4403227A3 (enExample)
JP (1) JP7280244B2 (enExample)
KR (1) KR20200037826A (enExample)
CN (2) CN111712257B (enExample)
AU (1) AU2018322776B2 (enExample)
BR (1) BR112020003842A2 (enExample)
CA (1) CA3073480A1 (enExample)
CO (1) CO2020001930A2 (enExample)
EA (2) EA201990183A1 (enExample)
GB (1) GB201713765D0 (enExample)
IL (1) IL272872B (enExample)
MX (1) MX2020002158A (enExample)
MY (1) MY197586A (enExample)
PH (1) PH12020500386A1 (enExample)
SA (1) SA520411426B1 (enExample)
SG (1) SG11202001537QA (enExample)
UA (1) UA126972C2 (enExample)
WO (1) WO2019043020A1 (enExample)
ZA (1) ZA202000388B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3831398A1 (en) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
JP2019532621A (ja) 2016-08-29 2019-11-14 サイオクサス セラピューティクス リミテッド 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP3916098A1 (en) * 2020-05-25 2021-12-01 Medizinische Hochschule Hannover Adenovirus for anti-tumour therapy
EP4161545A4 (en) * 2020-06-04 2024-09-11 Devacell, Inc. RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR102799318B1 (ko) 2020-08-11 2025-04-23 주식회사 카나프테라퓨틱스 Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
CN115161293B (zh) * 2021-04-01 2024-11-15 南京惟亚德生物医药有限公司 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用
CA3251570A1 (en) 2022-02-11 2025-07-09 Kanaph Therapeutics Inc. Pharmaceutical composition for the treatment of cancer comprising a fusion protein including IL-12, an anti-FAP antibody, and an anticancer agent
KR20230162310A (ko) 2022-05-20 2023-11-28 주식회사 카나프테라퓨틱스 Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
JP2025526409A (ja) 2022-07-28 2025-08-13 アカミス バイオ リミテッド 細胞療法を補完するための導入遺伝子をコードするウイルス
WO2024047114A1 (en) 2022-08-31 2024-03-07 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2015155370A1 (en) * 2014-04-12 2015-10-15 Psioxus Therapeutics Limited Group b adenovirus modified in the e4orf4 region
CN106062199A (zh) * 2013-12-23 2016-10-26 普西奥克瑟斯医疗有限公司 制造腺病毒和相应质粒的方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DE69435108D1 (de) 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5587299A (en) 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
CA2305269C (en) 1997-10-09 2012-07-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
JP4409097B2 (ja) 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
IL145447A0 (en) 1999-04-09 2002-06-30 Aventis Pharma Sa Composition for the preservation of infectious recombinant adenoviruses
DK1818408T3 (da) 1999-05-17 2011-10-17 Crucell Holland Bv Rekombinant adenovirus af serotypen Ad11
EP1181382B1 (en) 1999-06-01 2005-03-23 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
JP4921669B2 (ja) 2000-01-21 2012-04-25 バイオヴェックス リミテッド ウイルス株
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001092549A2 (en) 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
MXPA02012106A (es) 2000-06-06 2003-06-06 Bristol Myers Squibb Co Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion.
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US7459153B2 (en) 2001-01-04 2008-12-02 Wadell Goeran Viral vectors for gene therapy
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
AU2003206815A2 (en) 2002-02-01 2003-09-02 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with PODs
WO2003092594A2 (en) 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
AU2004260044B2 (en) 2003-07-18 2009-04-23 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
EP2292664B1 (en) 2003-10-16 2016-11-23 Amgen Research (Munich) GmbH Multispecific deimmunized CD3-binders
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
CN102816742B (zh) 2004-05-26 2014-04-09 普西奥克瑟斯医疗有限公司 用于治疗癌症的嵌合腺病毒
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
JP2008511336A (ja) 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
EP2094284A2 (en) 2006-12-22 2009-09-02 Bayer Schering Pharma AG Generation of oncolytic adenoviruses and uses thereof
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
MX339014B (es) 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
BRPI0919840B1 (pt) 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
AU2010301105A1 (en) 2009-10-02 2012-04-19 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
EP2486137B1 (en) 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
JP5981916B2 (ja) 2010-08-16 2016-09-07 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの構築方法
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
NO2748201T3 (enExample) 2011-08-23 2018-05-12
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ， エルエルシー 懸濁粒子送達システムおよび方法
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EP2964241A1 (en) 2013-03-05 2016-01-13 Baylor College Of Medicine Oncolytic virus
GB2519564A (en) 2013-10-24 2015-04-29 Shared Band Ltd Multicast transmission over bonded broadband
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
EP3831398A1 (en) * 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
HUE042829T2 (hu) 2014-04-03 2019-07-29 Igm Biosciences Inc Módosított J-lánc
JP2017529070A (ja) 2014-08-27 2017-10-05 サイオクサス セラピューティクス リミテッド アデノウイルスの製造方法
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
RU2725799C2 (ru) 2015-03-17 2020-07-06 Тилт Байотерапьютикс Ой Онколитические аденовирусы, кодирующие биспецифические антитела, а также способы и применения, связанные с ними
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
MX2018011306A (es) 2016-03-18 2019-08-16 Nantcell Inc Vector multimodal para infeccion de celulas dentriticas.
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
JP2019532621A (ja) 2016-08-29 2019-11-14 サイオクサス セラピューティクス リミテッド 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
SG11201903407XA (en) 2016-10-20 2019-05-30 Alpine Immune Sciences Inc Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CN106062199A (zh) * 2013-12-23 2016-10-26 普西奥克瑟斯医疗有限公司 制造腺病毒和相应质粒的方法
WO2015155370A1 (en) * 2014-04-12 2015-10-15 Psioxus Therapeutics Limited Group b adenovirus modified in the e4orf4 region

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cancer Associated Fibroblasts-Targeted Oncolytic Virus Results in Enhanced Antitumor Activity in Mouse Model;Feng Yu et al.;《Molecular Therapy》;第23卷;S246 *
Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein;Thomas Wuest et al.;《Journal of Biotechnology》;第92卷;159–168 *
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy;Carlos Alberto Fajardo et al.;《Cancer Research》;第77卷(第77期);2052-2063 *
Oncolytic Adenoviruses in Cancer Treatment;Ramon Alemany;《Biomedicines》;第2卷;36-49 *
新型双特异性单链抗体BiTEs及其在肿瘤治疗中的应用前景;于蕊等;《中国生物工程杂志》;第24卷(第24期);1-5 *

Also Published As

Publication number Publication date
AU2018322776B2 (en) 2023-04-06
EP4403227A3 (en) 2024-10-30
EA202090124A1 (ru) 2020-12-10
WO2019043020A1 (en) 2019-03-07
ZA202000388B (en) 2021-01-27
EP4403227A2 (en) 2024-07-24
IL272872A (en) 2020-04-30
AU2018322776A1 (en) 2020-03-12
US11840702B2 (en) 2023-12-12
CO2020001930A2 (es) 2020-06-09
US20240175052A1 (en) 2024-05-30
BR112020003842A2 (pt) 2020-09-08
EA201990183A1 (ru) 2019-07-31
CA3073480A1 (en) 2019-03-07
IL272872B (en) 2021-05-31
SG11202001537QA (en) 2020-03-30
JP2020531032A (ja) 2020-11-05
CN111712257A (zh) 2020-09-25
MY197586A (en) 2023-06-26
PH12020500386A1 (en) 2021-01-04
GB201713765D0 (en) 2017-10-11
JP7280244B2 (ja) 2023-05-23
SA520411426B1 (ar) 2023-02-20
UA126972C2 (uk) 2023-03-01
CN119432918A (zh) 2025-02-14
KR20200037826A (ko) 2020-04-09
EP3675904A1 (en) 2020-07-08
US20200216859A1 (en) 2020-07-09
MX2020002158A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
CN111712257B (zh) 携带双特异性T细胞衔接器（BiTE）的腺病毒
CN109862912B (zh) 携带双特异性t细胞衔接器的腺病毒
CN107690479B (zh) 编码b7蛋白质的溶瘤腺病毒
KR102857666B1 (ko) 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
CN108064159B (zh) 武装有异源基因的溶瘤腺病毒
CN111246867B (zh) 溶瘤病毒和方法
CN111989108A (zh) 利用rna去稳定元件协调基因表达
JP2023521410A (ja) 大型のアデノウイルスペイロードの組み込み
US20220152134A1 (en) Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
BR112016008973B1 (pt) Adenovírus oncolítico munido de genes heterólogos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Oxfordshire

Applicant after: Arcamis Biology

Address before: Oxfordshire

Applicant before: PSIOXUS THERAPEUTICS LTD.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant